GlobeNewswire by notified

AGC Biologics Receives Transatlantic Award for Investments in Milan Biopharmaceutical Industry

20.12.2021 14:05:00 CET | GlobeNewswire by notified

Share

Milan, Dec. 20, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it has won the 2021 Transatlantic Award from the American Chamber of Commerce in Italy (AmCham). The company was named the 2021 winner for its investments in the Italian biopharmaceutical industry, which includes expansion at its Center of Excellence in Milan to make it a global hub for cell and gene therapy innovation, development and manufacturing.

The annual award honors companies fostering economic development and growth between Italy and the United States. Luca Alberici, AGC Biologics General Manager and Site Head of the Milan facility, received the award on behalf of the company during the XV Transatlantic Award Gala Dinner, held on December 2 at Studio 90 East End Studios in Milan.

The additional guests of honor at the award ceremony included Mariangela Zappia (AmCham Italy Honorary President and Ambassador of Italy to the United States of America), Thomas D. Smitham (Chargé d’Affaires and interim and U.S. Embassy to Italy), On. Giancarlo Giorgetti (Italian Minister of Economic Development) and On. Lorenzo Guerini (Italian Minister of Defense).  AGC Biologics was honored alongside other notable companies such as Apple, Coca-Cola, Diasorin and KKR.

 “I am happy and honored to receive this award on behalf of AGC Biologics. This is an important award that showcases the investments our company has made in our Milan site, as well as the growing biopharmaceutical industry in our region,” said AGC Biologics Milan General Manager and Site Head, Luca Alberici. “Our Center of Excellence, one of the best in world and our team of scientists and employees, who work hard every day with responsibility and professionalism, played a crucial role in the successes we’ve achieved over the last two years.”

AGC Biologics acquired the Milan facility when it purchased Molecular Medicine S.p.A. ("MolMed") in 2020. Since that transaction, AGC Biologics has focused on supporting and developing the teams working at the site, and investing in expanding the site’s services, capabilities and production capacities. These commitments in the Milan facility have helped AGC Biologics become one of the most complete and active biotech CDMOs in the global healthcare market.

The AGC Biologics Milan site was the first GMP facility approved in Europe for ex-vivo gene therapy manufacturing and has industry-unique commercial manufacturing experience, having previously brought three cell & gene therapy products to the market.

To complement the Center of Excellence in Milan, the company recently opened a new facility in Longmont, CO., USA, which will help AGC Biologics expand its global capacity for cell and gene therapy development and manufacturing. Through these two key sites, AGC Biologics can now offer more capacity and services to pharmaceutical companies worldwide developing new life-changing cell and gene therapy products.

About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,000 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

FutureDial Automation Solutions Process Over 231 Million Preowned Mobile Phones Worldwide25.1.2022 14:30:00 CET | Press release

Growing adoption of FutureDial’s robotics and automation software by Wireless Carriers, Third-Party Logistics Providers (3PLs) and Mobile Device Recyclers led to explosive volumes of preowned iPhones and Android Smartphones being processed for resale in 2021 SUNNYVALE, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- FutureDial Incorporated continued its commanding lead in providing mobile device processing solutions for Wireless Carriers, Mobile Device Buy-Back & Trade-In Companies, Mobile Phone Recyclers and Third-Party Logistics Providers (3PLs) during the year, announcing that its robotics and automation software solutions have been used by customers in the mobile supply chain to data clear, functionally test and grade a cumulative total of over 231.4 Million pre-owned Android smartphones and iPhones worldwide, for resale on secondary markets. Additionally, the total number of functional tests using FutureDial software and robotics for quality assurance performed on preowned iPhones and A

HMNC Brain Health Expands International Patent Portfolio with Two Stress-axis Related Substances for Major Depressive Disorder25.1.2022 14:30:00 CET | Press release

In-Licensing arrangement with the renowned Max Planck Society, extends patent protection for clinical research and strengthens Nelivabon and Cortibon developmental projects The Company has also established an office in the United States, furthering global expansion strategy MUNICH, Germany, Jan. 25, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health, (“HMNC” or the “company”), a clinical stage biopharmaceutical company pioneering the development of personalized therapies in psychiatry, announced that it has expanded its international patent portfolio in the field of psychiatric therapy with two patent families claiming substances for treating stress-axis related Major Depressive Disorder. These license agreements are part of a broader collaboration with the renowned Max-Planck-Society, comprising biomarker patent claims and therapeutic patent claims covering markets in Europe, the U.S., and now Asia, in particular Japan. Utilizing a more personalized approach to discovering new drugs in psychi

Mandalay Resources fortsätter att presentera utmärkta resultat från utvidgningsborrningen i Björkdalsgruvans östra del25.1.2022 14:25:01 CET | Pressemelding

Ådror med synligt guld och höga halter indikerar en uppgradering på djupet i Björkdal TORONTO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) har nöjet att meddela en uppdatering om utvidgningsborrningen i de östra delarna av Björkdalsverksamheten i Sverige. Nya borrningshöjdpunkter: Utvidgning av centrala området 47,7 g/t guld över 11,7 m (uppskattad sann bredd ”ETW” 5,85 m) i MU21-052: Inklusive 1 056,0 g/t över 0,40 m;47,5 g/t guld över 6,4 m (ETW 4,11 m) i MU21-047: Inklusive 716,0 g/t över 0,31 m; och507,0 g/t guld över 0,45 m (ETW 0,23 m) i MU21-051. Utvidgningstestning av centrala området 45,5 g/t guld över 2,3 m (ETW 1,15 m) i MU21-028;83,1 g/t guld över 0,4 m (ETW 0,39 m) i MU21-029;8,4 g/t guld över 5,7 m (ETW 5,35 m) in MU21-030; och5,1 g/t guld över 8,0 m (ETW 6,13 m) i MU21-031. Centralt område – Länk till Lake-området 13,2 g/t guld över 1,0 m (ETW 0,94 m) i MU21-028; och19,3 g/t guld över 0,4 m (ETW 0

Exterro Announces Significant Industry Promotion of its Document Review Platform25.1.2022 14:00:00 CET | Press release

Latest Version of Revamped Exterro Review Platform Optimized for Entire Legal Ecosystem; Limited-Time Only Promotion offers up to 6-Months Free Use of Platform PORTLAND, Ore., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Exterro Inc. – the preferred provider of Legal GRC software specifically designed for in-house legal, privacy, and IT teams at Global 2000 and AmLaw 200 organizations – today announced, for a limited-time only, a promotion of up to 6 free months and 5 terabytes of data storage of its Review platform. The promotion coincides with Exterro’s ongoing build out of its Review business unit and updated feature capabilities that are now available to the entire legal ecosystem, including legal service providers, law firms and corporate clients. Furthermore, the promotion of Clay Cocalis to Chief Revenue Officer and the addition of Don McLaughlin, Senior Vice President, Review Software represents the significant investment the company is placing in Exterro Review to ensure greater market s

Shareholders’ proposals to the Annual General Meeting for the number of Marimekko’s Board members, the composition of the Board and its remuneration25.1.2022 14:00:00 CET | Press release

Marimekko Corporation, Stock Exchange Release, 25 January 2022 at 3.00 p.m. Shareholders’ proposals to the Annual General Meeting for the number of Marimekko’s Board members, the composition of the Board and its remuneration Shareholders representing in total approximately 27% of all of Marimekko Corporation’s shares and votes have made a proposal to the Annual General Meeting to be held on 12 April 2022 for the number of members of the Board of Directors, the composition of the Board and its remuneration. Proposal for the number of members of the Board of Directors Shareholders who represent approximately 27% of all of Marimekko Corporation’s shares and votes have informed the company that they propose to the Annual General Meeting that six (6) members be elected to the Board of Directors. Proposal for the composition of the Board of Directors The above-mentioned shareholders have also informed the company that they propose that Carol Chen, Mika Ihamuotila, Mikko-Heikki Inkeroinen and

RESULT OF RIKSBANK REVERSED AUCTIONS KOMMUNINVEST BONDS25.1.2022 11:07:00 CET | Press release

RESULT OF RIKSBANK REVERSED AUCTIONS KOMMUNINVEST BONDS Auction date2022-01-25Loan2311Coupon1.00 %ISIN-codeSE0010948240Maturity2023-11-13 Tendered volume, SEK mln500 +/- 250 Volume offered, SEK mln1,357 Volume bought, SEK mln500 Number of bids4 Number of accepted bids1 Average yield0.067 %Lowest accepted yield0.067 %Highest yield0.067 %% accepted at lowest yield 100.00 Auction date2022-01-25Loan2611Coupon1.00 %ISIN-codeSE0012569572Maturity2026-11-12 Tendered volume, SEK mln500 +/- 250 Volume offered, SEK mln1,699 Volume bought, SEK mln500 Number of bids6 Number of accepted bids3 Average yield0.725 %Lowest accepted yield0.722 %Highest yield0.730 %% accepted at lowest yield 54.55 Auction date2022-01-25Loan2805Coupon0.75 %ISIN-codeSE0015660139Maturity2028-05-12 Tendered volume, SEK mln500 +/- 250 Volume offered, SEK mln2,462 Volume bought, SEK mln500 Number of bids11 Number of accepted bids4 Average yield0.957 %Lowest accepted yield0.954 %Highest yield0.970 %% accepted at lowest yield 64.